COVID-19 & Respiratory Infections Questions

COVID overlaps heavily with flu and colds — fever, cough, tiredness, body aches, sore throat. Loss of taste or smell is more distinctive to COVID. Only a test can confirm which virus is causing symptoms. The main practical difference: COVID has caused more severe illness in older adults and people with chronic conditions, and can lead to longer-lasting fatigue (long COVID) even after mild infection.

Yes, especially if you'll be around older adults, pregnant women, or people with weak immunity — knowing lets you avoid spreading. Testing also matters if symptoms are severe enough that antiviral treatment might help (which needs to start early). Home rapid tests are widely available; PCR tests are more accurate. If you test positive, isolate as advised and monitor for worsening symptoms.

Long COVID is symptoms lasting more than 12 weeks after infection — commonly fatigue, brain fog, breathlessness, palpitations, and sleep problems. It can happen after even mild initial illness. Treatment is symptomatic and often multi-disciplinary (physiotherapy, pacing, mental health support, sometimes specific medications for individual symptoms). Long COVID clinics exist in major cities. Most people gradually improve over months but a subset have prolonged symptoms.

Keep their vaccinations current (annual flu, COVID boosters, pneumococcal). Wash hands before visiting, especially with a cough or cold. Skip in-person visits when you or family members are actively ill. Improve ventilation at home. Get help with chronic conditions well-controlled — diabetes and heart disease worsen respiratory infection outcomes. Have a plan for who takes them to hospital if needed.

Difficulty breathing at rest, chest pain, confusion, blue lips or fingertips, inability to keep fluids down, oxygen saturation below 94% on a home pulse oximeter, or fever that's very high or lasting more than a few days. In children, look for fast breathing, chest indrawing, or refusal to feed. Don't wait — respiratory illness can worsen fast, especially in older adults.

Latent TB means the M. tuberculosis bacteria are in your body but contained by your immune system inside granulomas, you have no symptoms, are not infectious, and cannot spread the disease. Chest X-ray is usually normal; TB is detected only through Mantoux test or IGRA blood test. Active TB means the bacteria have broken out of containment and are multiplying, causing symptoms (persistent cough, weight loss, night sweats, low-grade fever) and making you infectious to others. Roughly 5-10% of people with latent TB will develop active TB at some point in their lifetime, with the risk highest in the first 2 years after exposure and in anyone whose immune system weakens (HIV, diabetes, steroids, TNF inhibitors, aging). Whether latent TB needs treatment depends on individual risk. WHO recommends preventive treatment for household contacts of active TB cases, HIV-positive people, people starting immunosuppressive drugs, and healthcare workers with recent conversion. India's NTEP is expanding preventive TB treatment access, particularly for household contacts.

A positive RDT confirms malaria and shifts focus immediately to two things: (a) determining severity, a doctor evaluates whether it is uncomplicated malaria (treatable at home with oral antimalarials) or severe malaria (needs hospitalisation and IV artesunate). Severe malaria indicators include altered consciousness, seizures, jaundice, dark urine, breathing difficulty, or extreme weakness. (b) identifying species, this determines the drug regimen. For P. falciparum in India, artemisinin combination therapy (ACT) is first-line; for P. vivax, chloroquine plus primaquine (primaquine treats the dormant liver stage to prevent relapse). The doctor will also order a follow-up blood smear to quantify parasite load and check response to treatment at day 3. Do not self-treat with over-the-counter antimalarials on a positive RDT, the wrong drug or dose can drive resistance and worsen outcomes.

RDTs use protein-based antibodies that degrade at high temperatures, accuracy drops meaningfully when kits are stored above 30°C for extended periods, which is a real issue in Indian summers and in rural clinics without air conditioning. Storage above 40°C can produce false negatives even for kits well within their expiry date. Practical implications: kits held in unrefrigerated pharmacy shelves during peak summer months (April-June) may perform worse than the manufacturer's stated sensitivity; kits transported without cold-chain protection in field settings often lose reliability. This is why WHO recommends RDT lot testing before deployment in endemic areas. For patients: if an RDT result seems inconsistent with your clinical picture, ask for a blood smear rather than trusting the RDT alone, the smear does not have storage-related accuracy issues.

Malaria RDT kits are available in India but not typically sold for home use, they are meant for clinical or field-worker settings and are usually sold to hospitals, primary health centres, NGOs, and pharmacies for point-of-care testing rather than direct-to-consumer. Even where available at retail pharmacies, home use is not recommended because: interpreting a faint test line correctly needs practice, a negative result does not rule out early-stage malaria and needs follow-up, and any positive result immediately needs a doctor visit for treatment (antimalarials are prescription-only). Practical alternative: same-day RDT plus blood smear at a diagnostic lab or general practitioner clinic is inexpensive and available in most Indian cities. Do not delay treatment while trying to diagnose at home if you have symptoms consistent with malaria after mosquito exposure.

Getting infected and getting sick are two different things. Roughly one-third of the global population carries M. tuberculosis in latent form after some exposure, but only 5-10% ever develop active disease. Whether you progress from infection to active disease depends on multiple factors: immune status (HIV infection multiplies risk 20-30 times, diabetes doubles risk, aging weakens immunity), nutritional status (malnutrition dramatically increases risk), co-existing lung damage (smoking, silicosis, previous TB), genetic factors (specific HLA variants affect susceptibility), medications suppressing immunity (steroids, chemotherapy, TNF inhibitors), and the initial infecting dose. In India, the confluence of high HIV in some regions, high diabetes prevalence (over 100 million adults), household crowding, and undernutrition explains why India carries such a disproportionate share of the global TB burden despite decades of control efforts.

BCG (Bacillus Calmette-Guérin) vaccine has real but limited effectiveness. It reliably prevents severe childhood forms of TB. TB meningitis and disseminated (miliary) TB, with efficacy of 60-80%. It is far less effective at preventing adult pulmonary TB, with published efficacy ranging from 0% to 80% depending on the population studied, the variability itself is a major research puzzle, possibly related to prior exposure to environmental mycobacteria in different geographies. Despite this variability, India continues universal BCG vaccination at birth because the severe childhood TB prevention justifies it in a high-burden country; deaths from meningitis or miliary TB in unvaccinated Indian infants would be substantial. Improved TB vaccines are in active development globally (M72/AS01E is in phase 3 trials), but until one is approved, BCG remains standard for Indian newborns and provides genuine protection for the childhood forms that matter most in the neonatal period.

MDR-TB is TB resistant to at least isoniazid and rifampicin, the two most powerful first-line drugs. This resistance usually develops when patients receive inadequate treatment (wrong drugs, wrong doses, insufficient duration, or interruption), surviving bacteria multiply and become resistant. XDR-TB (extensively drug-resistant TB) is even more resistant, adding resistance to fluoroquinolones and injectable second-line drugs. India has among the largest number of MDR-TB cases globally. Treatment takes 9-24 months (vs 6 months for drug-sensitive TB), involves 4-7 medications simultaneously, causes more side effects, costs significantly more, and has lower cure rates (roughly 60-75% vs 85-95% for drug-sensitive TB). India's NTEP provides free MDR-TB diagnosis (GeneXpert MTB/RIF plus line probe assays) and treatment through dedicated DR-TB centres. Key patient rule: never stop TB treatment early even when feeling better, never skip doses, never take TB medications from unknown sources, creating MDR-TB harms both the patient and the community for decades.

Modern malaria RDTs have sensitivity of roughly 90-95% for detecting Plasmodium falciparum at typical fever-onset parasite levels, meaning they catch most cases but can miss around 5-10%. Sensitivity for P. vivax is lower, around 80-90%, because the antigens vary more across strains. Sensitivity drops significantly when parasite counts are very low (early in the illness or in asymptomatic carriers). Blood smear microscopy remains the gold standard, with sensitivity approaching 95% in expert hands and the ability to identify species and quantify parasite load. In practice, RDT is the fast first test almost anywhere in India; blood smear confirms the diagnosis and guides treatment intensity. A negative RDT with persistent malaria-suggestive symptoms should always trigger a follow-up smear rather than being taken as definitive.

Very urgent, especially if you have travelled to sub-Saharan Africa, the Indian North-East, Odisha, Chhattisgarh, or parts of South-East Asia where P. falciparum is common. Get tested the same day. P. falciparum malaria can progress to severe disease within 24-72 hours of first symptoms, cerebral malaria, kidney failure, severe anaemia, ARDS. Tell the doctor exactly where you travelled, when, and whether you took prophylaxis. If travel was to a P. vivax or P. ovale region, symptoms can appear weeks to months after return because these species can lie dormant in the liver, any unexplained fever within a year of travel to an endemic zone warrants a malaria test, not just antibiotics for a presumed viral illness.

A negative RDT does not rule out malaria, especially in the first 24-48 hours of illness or in P. vivax infection where parasite levels can be low. Next steps: (a) request a thick and thin blood smear read by an experienced microscopist, this is more sensitive than an RDT and identifies the species; (b) if smear is also negative but fever continues past 48 hours, repeat the smear, parasitemia rises with each fever cycle and can become detectable; (c) discuss PCR testing at a tertiary centre if smears remain negative but symptoms are strongly suggestive; (d) in parallel, work up other causes of fever in India, dengue, typhoid, chikungunya, leptospirosis, urinary infection, since these can co-exist or mimic malaria.

In government hospitals, both RDT and blood smear are typically free or nominal. In private labs, RDT and blood smear together are usually affordable and results come back the same day. RDT within 20-30 minutes, smear within 2-4 hours if the lab has a technician on shift. PCR is only available at larger hospitals and reference laboratories; it is significantly more expensive and takes 24-72 hours depending on the batch schedule. For anyone with fever in an endemic area, testing should not be delayed by cost, a delayed diagnosis in P. falciparum malaria can escalate to cerebral malaria within days.

The NS1 antigen appears in blood as early as day 1 of fever and stays detectable through roughly day 5-7. That is the window where NS1 is most sensitive. If you have fever with any classic dengue features, sudden high fever, severe body aches (especially behind the eyes), headache, nausea, or a rash, and you are anywhere in India during monsoon or early post-monsoon (June-November), ask your doctor about NS1 on the same day fever starts. Waiting past day 5 makes NS1 progressively less sensitive; after day 7, IgM antibody test becomes more useful. Testing on day 0-1 of fever occasionally gives false negatives because viral load has not yet peaked, a repeat test 24-48 hours later resolves this.

Three different things at three different time points. NS1 detects a viral protein made by the dengue virus itself, positive from day 1-7, catches active infection early. IgM antibody appears from day 5-7 onwards and stays positive for 2-3 months, catches recent infection, useful when NS1 window has passed. IgG antibody appears from day 7-14 and stays positive for years, indicates past infection or immunity, not useful for diagnosing current fever alone. In practice, doctors often order NS1 + IgM together in the first week of fever, since together they cover the whole infection window. IgG is only useful in specific situations like distinguishing primary vs secondary dengue (secondary infection has higher risk of severe dengue).

A positive NS1 confirms dengue and shifts the focus to monitoring for complications, since there is no antiviral treatment. Immediate steps your doctor will typically arrange: (a) baseline CBC to check platelet count and hematocrit; (b) monitoring platelet count daily during the critical phase (day 3-7 of fever), platelets can drop rapidly; (c) hydration guidance, oral or IV fluids as needed, particularly during the fever-defervescence phase which is when severe dengue often develops; (d) avoiding aspirin, ibuprofen, and other NSAIDs because they raise bleeding risk in dengue, paracetamol (acetaminophen) is the only safe antipyretic; (e) hospitalisation if warning signs appear (severe abdominal pain, persistent vomiting, bleeding from gums or nose, lethargy, cold extremities). The critical period is when fever breaks around day 4-6, that is the window to watch most carefully, not the fever itself.

A negative NS1 does not rule out dengue, especially in the first 24-48 hours of fever (viral load may not yet be at detectable levels) or after day 5-7 (NS1 window has closed). Practical next steps: (a) if you tested on day 1-2 of fever, repeat NS1 after 24-48 hours, sensitivity improves as viral load rises; (b) if fever has been going 5+ days, ask for IgM antibody test which becomes positive around day 5-7; (c) simultaneously rule out other Indian monsoon fevers with overlapping symptoms, malaria (blood smear + RDT), typhoid (Widal or blood culture), leptospirosis, chikungunya, and viral hepatitis all present similarly. Do not assume 'just viral fever' if fever continues past 48-72 hours without a diagnosis, return to your doctor for expanded workup rather than waiting it out at home.

NS1 (nonstructural protein 1) is a glycoprotein made by the dengue virus during its replication inside human cells. It is secreted into the bloodstream in large quantities from day 1 of infection, reaching detectable levels typically within 24 hours of fever onset and remaining detectable through roughly day 5-7. This early appearance makes NS1 uniquely useful because it fills the diagnostic gap before your body has produced detectable antibodies (IgM appears around day 5-7, IgG around day 7-14). NS1 is highly specific to flaviviruses (dengue, Zika, yellow fever), so a positive result in an Indian patient with fever during dengue season is almost certainly dengue, since Zika and yellow fever are rare here. Testing methods: ELISA is the lab standard (highest sensitivity); rapid diagnostic test (RDT) kits give point-of-care results in 15-30 minutes with slightly lower sensitivity.

Both detect the same NS1 antigen but differ in sensitivity, turnaround, and cost. NS1 ELISA (enzyme-linked immunosorbent assay): performed in a diagnostic laboratory, sensitivity typically 85-95%, results in 4-24 hours depending on lab batching, moderate cost. This is the standard reference test. NS1 rapid diagnostic test (RDT) kits: performed at point-of-care (clinic, small lab, some pharmacies), sensitivity typically 70-85%, results in 15-30 minutes, lower cost. RDTs are useful when time matters and lab access is limited, a positive RDT is highly reliable, but a negative RDT should ideally be confirmed with ELISA if clinical suspicion remains high. In India during dengue outbreaks, RDT-first-then-ELISA-if-negative is a common approach, particularly outside tier-1 cities where lab turnaround can slow the diagnosis.

In principle yes. NS1 tests can show cross-reactivity with other flaviviruses because these viruses share protein structures. In practice for Indian patients this is rarely a clinical issue: Zika virus is uncommon in India (small outbreaks reported), yellow fever is not endemic in India (a few imported cases), and Japanese encephalitis (JE) does exist but the clinical presentation differs enough that dengue vs JE is usually distinguishable clinically. For most Indian patients with fever and a positive NS1 test during dengue season, the result reliably indicates dengue. Where confusion can arise: recent yellow fever vaccination (given for international travel) or recent JE vaccination can occasionally cause transient antibody cross-reactivity, though this affects IgM tests more than NS1 antigen tests. If cross-reactivity is a genuine concern (post-travel, unusual clinical picture), confirmatory testing with dengue-specific PCR resolves it.

A negative NS1 test does not rule out dengue, it needs interpretation in context of when in the illness you tested. Common reasons for a false-negative NS1: (a) tested too early (first 24 hours of fever, viral load still rising below detection threshold); (b) tested too late (after day 5-7, NS1 has cleared from blood but antibodies are now present); (c) secondary dengue infection in someone previously infected with a different serotype, pre-existing IgG antibodies bind NS1 and reduce its detectability; (d) infection with certain P. vivax-like less common serotypes with lower NS1 production. Next steps for a symptomatic patient with negative NS1: repeat NS1 in 24-48 hours if still within day 1-5 window, or add IgM antibody test if past day 5, or PCR testing at a tertiary centre for definitive diagnosis. Do not accept 'ruled out dengue' from a single NS1 without considering timing, one test does not close the case if symptoms strongly suggest dengue.

The three anchor diagnoses in most cases: Hyperthermia related to underlying infection or inflammatory process (as evidenced by elevated body temperature above 38°C, warm skin, tachycardia); Deficient Fluid Volume or Risk for Deficient Fluid Volume related to excessive fluid loss from vomiting and insensible loss from fever (evidenced by decreased urine output, dry mucous membranes, tachycardia, hypotension); and Nausea related to gastrointestinal irritation, drug side effects, or central causes (evidenced by patient report and observed retching). Secondary diagnoses to consider based on presentation: Risk for Electrolyte Imbalance, Acute Pain (headache or abdominal), Imbalanced Nutrition Less than Body Requirements if vomiting is protracted, and Risk for Infection Transmission when the underlying cause is a communicable pathogen. Priority ordering follows Maslow, fluid balance first, then temperature, then comfort.

At minimum every 4-6 hours during the acute phase: temperature (route consistent, oral, axillary, or tympanic; note the route), heart rate, blood pressure (including orthostatic if the patient is ambulant), respiratory rate, oxygen saturation, level of consciousness, and pain score. Fluid balance: strict intake and output charting, urine specific gravity or colour observation, weight if possible daily at the same time. Vomiting characterisation: frequency, volume, colour and content (bilious, coffee-ground, undigested food, blood), and relation to food or medication. Assess mucous membranes, skin turgor, and capillary refill each shift for hydration status. In endemic Indian settings, note any petechiae, rash, or bleeding, early signs of severe dengue that shift the care plan significantly.

Establish IV access early, deteriorating patients can lose the option to hydrate orally quickly. Initiate rehydration per protocol (oral rehydration solution if tolerated; IV normal saline or Ringer's lactate if vomiting persists or dehydration is significant), correcting electrolyte deficits based on baseline labs. Administer prescribed antipyretic (paracetamol is first-line; avoid NSAIDs if dengue is on the differential due to bleeding risk) and prescribed antiemetic (ondansetron is common first-line for adults; metoclopramide alternatives). Cooling measures: tepid sponging if temperature is over 39°C, adequate exposure, ambient temperature control. Send off diagnostic samples early. CBC, electrolytes, urea/creatinine, urine routine, and pathogen-specific tests based on epidemiology (dengue NS1, malaria smear, typhoid Widal or blood culture, stool if diarrhoea present). Document baseline for evaluation.

Objective indicators of successful intervention within 24-48 hours: temperature trending down toward 37.5°C or lower without persistent antipyretic dependence; vomiting frequency reduced by at least 50%, patient tolerating small oral fluid volumes; urine output restored to at least 0.5 mL/kg/hour with clearing urine colour; heart rate and blood pressure normalising toward baseline; improving level of consciousness and patient-reported comfort. Red flags requiring escalation to the treating physician: persistent fever above 39°C beyond 48 hours of appropriate antipyretic use, worsening tachycardia despite fluid replacement, oliguria, altered mental status, new bleeding manifestations (particularly relevant in the Indian dengue season), rising creatinine, or persistent inability to tolerate oral intake. The care plan is not a static document, nursing diagnoses should be re-prioritised as the aetiology clarifies from diagnostic workup.

Neither. Malaria is caused by a single-celled parasite called Plasmodium, technically a protozoan, one of the oldest kinds of life on earth. Five species infect humans: P. falciparum (the most dangerous, common in Africa and parts of India's North-East and eastern states), P. vivax (the most widespread in India, causes relapsing infections), P. ovale, P. malariae, and P. knowlesi (rare, mainly South-East Asian forest exposure). Because it is a parasite and not a bacterium or virus, malaria does not respond to antibiotics or antiviral medicines. It needs specific antimalarial drugs, chloroquine, artemisinin-based combinations, or primaquine, depending on the species and drug-resistance pattern in the region.

The bite injects fewer than a hundred parasite sporozoites into your bloodstream, a tiny number, but they head straight for the liver within an hour. Inside a liver cell, each sporozoite multiplies silently over 7-30 days into tens of thousands of new parasites (merozoites). When the liver cell bursts, those merozoites flood into your bloodstream and start invading red blood cells. Each infected red cell then bursts every 48-72 hours, releasing more parasites, and this is when you first feel sick. So the mosquito bite is small, but the liver stage is a hidden multiplier that turns a handful of parasites into millions before symptoms even begin.

Because the parasite's blood-stage cycle is synchronised. All the infected red blood cells burst at roughly the same time, every 48 hours for P. vivax and P. ovale (tertian fever), 48 hours for P. falciparum (though often less regular), and 72 hours for P. malariae (quartan fever). Each mass rupture releases parasites plus toxic parasite waste products into the bloodstream, which triggers the immune system to spike fever, chills, and shivering, the classic malaria paroxysm. Between paroxysms, the parasite is quietly invading fresh red blood cells and you feel relatively normal. This cyclical pattern is so distinctive that a fever every other day in someone who has been in an endemic area should trigger a malaria test even before other symptoms develop.

Both P. falciparum and P. vivax are prevalent in India but they behave differently. P. falciparum is more common in Odisha, Chhattisgarh, Jharkhand, and the North-East and causes almost all severe and fatal malaria, cerebral malaria, kidney failure, ARDS, severe anaemia. It progresses fast and can kill within days if untreated. P. vivax is more widespread across the country and causes fewer deaths but has two features that matter: relapses can occur months to years after the original infection because dormant liver-stage parasites (hypnozoites) can reactivate, and chronic P. vivax weakens people over time. Any fever after being in a mosquito-endemic area should be tested regardless of which species is more common there, waiting to see if it is just viral fever can be dangerous with P. falciparum.

Ask for a peripheral blood smear as your primary test, thick smear for detection, thin smear for species identification. A rapid diagnostic test (RDT) is a reasonable add-on, especially if you are in a smaller clinic or evening hours when a microscopist may not be available; RDT gives a result in 15-20 minutes. If both are negative but fever and symptoms persist for another 24-48 hours, a repeat smear at a good centre or a PCR test at a tertiary hospital is the next step. Do not rely on RDT alone if your clinical picture is convincing, low-parasitemia infections and non-falciparum species (P. vivax, P. ovale) can be missed by rapid tests.

A negative test can be a real false-negative — the disease is there but the test missed it. The commonest reasons: parasite load is too low to detect (early infection, or partial treatment already given at home), the sample was taken between fever peaks when parasites are hiding inside cells, the RDT antigen has degraded due to bad storage, or the falciparum strain doesn't make HRP2 (a real problem in some African countries and now surfacing globally). Skill matters too — reading a blood smear well takes training. If clinical suspicion is high — persistent fever, recent travel to an endemic area, chills, jaundice — the doctor will repeat the smear every 12–24 hours for up to three days before ruling out malaria, or move to PCR. A single negative test is not enough to close the case.

Confusion, seizures, extreme weakness, breathlessness and dark or reduced urine mean the malaria has turned severe. Cerebral malaria (mostly from P. falciparum) causes altered consciousness, seizures and coma. Other severe features include very low haemoglobin, respiratory distress, kidney failure (sometimes called blackwater fever from dark urine), dangerously low blood sugar and metabolic acidosis. Children under five, pregnant women, elderly people and anyone with a weakened immune system are at highest risk. Any fever plus one of these signs after a mosquito bite or travel to a malaria area needs emergency hospital care — severe malaria can kill within 24 hours if untreated.

A blood test confirms malaria within minutes, and treatment usually cures it in 3–7 days if started early. Doctors diagnose malaria by looking at a stained blood smear under the microscope — this identifies the species and how many parasites are present. Rapid diagnostic tests (RDTs) give a result in 15–20 minutes from a finger-prick sample and are widely used in clinics and endemic areas. PCR is used in complex or research cases. Treatment depends on the species and severity: uncomplicated cases usually get artemisinin-based combination therapy (ACT) for three days; severe malaria needs intravenous artesunate in hospital plus supportive care. P. vivax and P. ovale also need a drug like primaquine to clear liver-stage parasites and prevent relapse.

You cannot confirm it at home — but the pattern of fever and the type of pain give strong clues before a blood test. Malaria fever usually comes in cycles every 48 or 72 hours with shaking chills followed by sweats, and often causes pallor, jaundice or dark urine because red blood cells are being destroyed. Dengue fever is typically sudden, very high (up to 40°C) and continuous rather than cyclic, with severe pain behind the eyes, intense muscle and joint pain ("breakbone fever"), skin rash and sometimes bleeding from the nose or gums. Both start after a mosquito bite. Any high fever lasting more than two days — especially with these clues — needs a same-day blood test to confirm the diagnosis.

Malaria comes from the Anopheles mosquito, which bites mostly at night; dengue comes from Aedes, which bites during the day. The Anopheles mosquito carries Plasmodium parasites and prefers dusk-to-dawn feeding, so bed nets and evening protection matter most for malaria. The Aedes aegypti mosquito carries dengue virus and bites mainly in the early morning and late afternoon, breeding in clean stagnant water inside homes — coolers, flower pots, discarded tyres, plastic containers. That is why dengue control focuses on removing indoor water sources while malaria control leans more on outdoor spraying and bed nets. During monsoon both mosquito populations rise together, which is why dengue and malaria outbreaks often overlap in the same weeks.

Bleeding, confusion, severe abdominal pain, breathing trouble or reduced urine mean the illness has turned severe and needs emergency care. For dengue, warning signs typically appear as the fever drops on day 3–5: severe abdominal pain, persistent vomiting, bleeding from gums or nose, blood in vomit or stool, rapid breathing, cold clammy skin and drop in platelet count. This phase can progress to dengue shock syndrome within hours. For malaria, danger signs include confusion, seizures, extreme weakness, jaundice, dark urine and breathing difficulty — usually pointing to cerebral malaria or severe organ involvement. Any of these signs, in either infection, means hospital admission, not home care.

Malaria has specific drugs that kill the parasite; dengue has no antiviral drug, so treatment is supportive. For malaria, once the species is identified, doctors use artemisinin-based combination therapy (ACT) for three days in uncomplicated cases; severe malaria needs intravenous artesunate. P. vivax also needs primaquine to prevent relapse from liver-stage parasites. For dengue, there is no specific antiviral — treatment focuses on fluids (oral or IV depending on severity), paracetamol for fever, monitoring of platelet count and haematocrit, and hospital care if warning signs appear. Aspirin and ibuprofen are avoided in suspected dengue because they raise the risk of bleeding. Never self-treat suspected malaria or dengue — both need blood-test confirmation and doctor supervision.

Yes — TB can leave the lungs and settle in bones and joints, and the spine is the single most common site. This form is called skeletal or bone TB, and spinal TB specifically is known as Pott's disease. The infection reaches the bone through the bloodstream, usually from a lung or lymph-node source that may itself be silent by the time the bone disease shows up. Around 1–3% of all TB cases involve bone, with the spine accounting for roughly half of these; the hip and knee are the next most common. Because it develops slowly over months, bone TB is often mistaken for ordinary back pain, arthritis or a sports injury, and diagnosis is frequently delayed.

Persistent, deep bone pain that gets worse at night, along with low-grade evening fever, unexplained weight loss and night sweats, are the classic warning signs. In spinal TB the pain is usually in the mid or lower back and doesn't improve with rest or painkillers. Local swelling, restricted movement of the affected joint and eventually a visible bump on the back (kyphosis, or hunchback) can develop as vertebrae collapse. A cold abscess — a soft, painless swelling without redness or warmth — sometimes appears near the spine, groin or thigh. Neurological symptoms like leg weakness, numbness or difficulty passing urine are red flags for spinal cord compression and need urgent evaluation.

MRI is the most sensitive test for bone and spinal TB — it shows early bone marrow oedema, disc destruction, cold abscesses and any pressure on the spinal cord well before X-rays do. X-rays and CT scans help see bone destruction and deformity. To confirm the diagnosis, doctors take a biopsy of the affected bone or the pus from a cold abscess and send it for microscopy, TB culture and molecular tests like GeneXpert MTB/RIF, which also flags rifampicin resistance within hours. Blood tests (ESR, CRP) support the diagnosis but cannot confirm it. Chest X-ray is done to check whether the lungs are also involved, since around half of bone TB cases have a hidden pulmonary focus.

Bone TB is treated with the same four anti-TB drugs used for lung TB — isoniazid, rifampicin, ethambutol and pyrazinamide — but for longer, usually 9 to 12 months in total. The first two months use all four drugs; the remaining months use isoniazid and rifampicin. Bed rest, a brace to support the spine and gradual physiotherapy help protect the bone while it heals. Surgery is reserved for specific situations: severe spinal deformity, spinal cord compression not responding to medicines, large abscesses that need drainage or an unstable spine that needs fusion. Most people recover fully if treatment is started before major bone destruction, so early diagnosis really is the difference between full recovery and permanent disability.

The three highest-priority NANDA-I diagnoses for pulmonary TB are Ineffective Airway Clearance, Risk for Infection Transmission, and Imbalanced Nutrition: Less Than Body Requirements. Ineffective Airway Clearance — related to thick, tenacious sputum and bronchospasm secondary to Mycobacterium tuberculosis infection, as evidenced by productive cough, abnormal breath sounds, and dyspnea — is first priority because impaired airway clearance directly threatens oxygenation and increases the risk of respiratory failure in severe cases. Risk for Infection Transmission is equally critical from a public health standpoint: TB is airborne, and a smear-positive patient can infect 10–15 people per year without proper isolation precautions. Imbalanced Nutrition is third priority because TB is a wasting disease — the infection drives a hypermetabolic state, while anorexia, nausea from antitubercular drugs, and fatigue all reduce oral intake. Additional diagnoses to include: Activity Intolerance (related to weakness, fever and dyspnea), Ineffective Health Maintenance (related to complex 6-month DOTS regimen), and Anxiety (related to stigma and prolonged treatment). In TB-specific NCP examinations, students are expected to identify infection transmission risk as a separate nursing responsibility alongside the patient's own clinical problems.

Infection control is a shared nursing and public health responsibility in TB care. The primary intervention is airborne precaution isolation: the patient should be placed in a negative-pressure single room (or in a well-ventilated room with windows open if a formal isolation room is not available). The nurse must wear an N95 respirator — not a surgical mask — when entering the room; surgical masks protect the patient, not the nurse, from airborne droplet nuclei. Teach the patient to cover the mouth and nose with a triple-layered surgical mask or a tissue when coughing or sneezing (respiratory hygiene/cough etiquette), and to dispose of sputum-soaked tissues in a sealed bag. Handle sputum specimens as biohazard material. Ensure DOTS (Directly Observed Treatment, Short-course) compliance: the nurse or a trained health worker directly watches the patient swallow each dose of antitubercular drugs (Isoniazid, Rifampicin, Pyrazinamide, Ethambutol in the intensive phase). Non-adherence is the leading cause of drug resistance and prolonged infectiousness. Facilitate contact tracing — identify close contacts (household members, co-workers) and refer them for tuberculin skin test or IGRA testing. Document isolation precautions, sputum smear status, and every DOTS administration in the nursing record. Isolation can generally be discontinued once the patient has three consecutive negative sputum smears on separate days and has been on effective therapy for at least two weeks.

Nutritional rehabilitation is essential to TB recovery because undernutrition impairs cell-mediated immunity, which is the primary defence against Mycobacterium tuberculosis. The nurse's role is to assess nutritional status at admission (BMI, mid-upper arm circumference, serum albumin if available) and monitor weekly weight. Set a nutritional goal: TB patients should consume at least 35–40 kcal/kg/day and 1.2–1.5 g protein/kg/day to rebuild lean mass and support immune function. Advise a high-calorie, high-protein diet: pulses, legumes, eggs, fish, chicken, low-fat dairy (paneer, curd), whole grains, and fresh fruits and vegetables rich in vitamins A, C, and E. Isoniazid depletes vitamin B6 (pyridoxine), so ensure the patient is prescribed pyridoxine 25–50 mg daily alongside antitubercular therapy to prevent peripheral neuropathy. Manage common nutritional barriers: nausea and loss of appetite from Rifampicin and Pyrazinamide are worst in the first 2–4 weeks — advise taking drugs with a light snack (not a heavy meal) if nausea is severe; offer small, frequent meals every 2–3 hours rather than three large meals. Refer to a dietitian if BMI is below 17 or if the patient has comorbid diabetes (insulin requirements change as TB treatment progresses and nutrition improves). Document dietary intake and weight weekly; a patient gaining weight steadily is responding to treatment.

Discharge education is critical because TB treatment continues for 6 months (standard regimen) or longer (MDR-TB), entirely at home after the intensive phase. Cover these six areas: (1) Drug adherence — explain that stopping drugs early is the single biggest cause of MDR-TB; link the patient into the local DOTS centre or PHC for continued supervised therapy; give the DOTS worker's contact number. (2) How TB spreads and how to protect the family — open windows for ventilation, sleep in a separate room if possible, wear a mask during the infectious period (first two weeks of treatment), and avoid crowded enclosed spaces. (3) Recognition of drug side effects — yellow eyes or urine (rifampicin colours urine orange-red, which is normal, but yellow sclera means hepatotoxicity; stop drugs and report immediately), tingling hands or feet (pyridoxine deficiency from isoniazid — take B6 supplement), visual disturbance (ethambutol-related optic neuritis — report immediately). (4) Diet — high-protein, high-calorie meals; no alcohol (increases hepatotoxicity risk). (5) Follow-up schedule — sputum smear at 2 months, 5 months and 6 months; chest X-ray at 2 and 6 months; liver function test monthly in the first 2 months. (6) TB notification — inform the patient that TB is a notifiable disease; the treating facility reports to the district TB officer, which triggers contact tracing for household members.

Yes, most adults benefit from at least the hepatitis B vaccine, and many should also get hepatitis A depending on their risk. Hepatitis B is a major cause of chronic liver disease, cirrhosis and liver cancer, and it spreads through blood, sexual contact, and shared needles — the WHO recommends universal vaccination for all adults who were not vaccinated in childhood. Hepatitis A spreads through contaminated food and water, so people travelling to areas with poor sanitation, those with chronic liver disease, healthcare workers, food handlers, and men who have sex with men are strongly advised to get it. Vaccination is safe, inexpensive, and gives long-lasting protection — usually decades — from two life-changing infections.

Hepatitis A needs 2 doses six months apart; hepatitis B needs 3 doses on a 0, 1, and 6-month schedule. For hepatitis A, the first shot gives short-term protection within 2–4 weeks; the second shot 6 months later locks in long-term immunity — usually 20+ years. For hepatitis B, the standard schedule is dose 1 at the start, dose 2 one month later, and dose 3 five months after that — the third dose is essential for durable immunity. A newer 2-dose adult hepatitis B vaccine (Heplisav-B) uses shots one month apart and is now available in some countries. A combination hepatitis A + B vaccine also exists and follows a 3-dose schedule (0, 1, 6 months). Missing a dose usually means completing the series later, not restarting.